Don't forget there is a 40% efficacy hurdle to overcome, which is the amount of variability allowed in the screening visits between PSG-1 and PSG-2. We've got to get an efficacy effect beyond the allowed 40% variability before it counts. Of course 40% was the maximum allowed to get into the trial, so some patients were hopefully well below that degree of variability.
Market Data 
Markets 
AI
